NCT06149286 2026-03-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
13 trialsNCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04712097 2026-02-04
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT01321541 2021-11-19
PIX-R
CTI BioPharma
Phase 3 Completed
NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT00384150 2015-11-26
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00363636 2015-10-02
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00078598 2005-11-09
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Corixa Corporation
Phase 3 Unknown